MedPacto Obtains Domestic Patent Rights Related to 'BAG2 Antibody'

[Asia Economy Reporter Kum Boryeong] MedPacto announced on the 27th that it has acquired a domestic patent related to 'Composition for cancer diagnosis using BAG2 antibody and method thereof.'

MedPacto stated, "Our company is developing a diagnostic kit (MO-B2) aimed at diagnosing cancer metastasis and recurrence using BAG2, which we discovered for the first time in the world as a biomarker," adding, "We signed a contract with Thermo Fisher Scientific in early August to conduct research for commercialization and production of the diagnostic kit."